Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia

Disease Markers

Volumn 30, Issue 4, 2011, Pages 191-196

  Bodova, Kristina Biskupska ^a   Biringer, Kamil ^a   Dokus, Karol ^a   Ivankova, Jela ^a   Stasko, Jan ^a   Danko, Jan ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

fibronectin; gestational hypertension; PAI 1; Preeclampsia; uterine artery Doppler

Indexed keywords

FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GESTATION PERIOD; HUMAN; LASER DOPPLER FLOWMETRY; MATERNAL PLASMA; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SECOND TRIMESTER PREGNANCY; UTERINE ARTERY; WAVEFORM;

UTA;

EID: 79959748074     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2011/219350     Document Type: Article

References (22)

1. M.L. Tjoa, C.B. Oudejans, J.M. van Vugt et al., Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction, Hypertens Pregnancy 23(2) (2004), 171-189. (Pubitemid 39096213)
2. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia.Number 33, January 2002.American College of Obstetricians and Gynecologists, Int J Gynaecol Obstet 77(1) (2002), 67-75.
3. L. Belo, A. Santos-Silva, A. Rumley et al., Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in preeclampsia: correlation with proteinuria, BJOG 109(11) (2002), 1250-1255. (Pubitemid 36164752)
4. B.M. Sibai, S. Caritis and J. Hauth, What we have learned about preeclampsia, Semin Perinatol 27(3) (2003), 239-246. (Pubitemid 36828961)
5. F. Lyall, Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia, Aust N Z J Obstet Gynaecol 46(4) (2006), 266-273. (Pubitemid 43984941)
6. M. Noris, N.Perico and G. Remuzzi, Mechanism od Disease: pre-eclampsia, Nat Clin Pract Nephrol 1(2) (2005), 98-114.
7. E. Ostlund, L.O. Hansson and K. Bremme, Fibronectin is a marker for organ involment and may reflect the severity of preeclampsia, Hypertens Pregnancy 20(1) (2001), 79-87. (Pubitemid 32672930)
8. R. Pankov and K.M. Yamada, Fibronectin at a glance, J Cell Sci 115(20) (2002), 3861-3863. (Pubitemid 35256486)
9. T. Aydin, F.G. Varol and N.C. Sayin, Third trimester maternal plasma total fibronectin levels in pregnancy-induced hypertension: results of a tertiary center, Clin Appl Thromb Hemost 12(1) (2006), 33-39. (Pubitemid 43221569)
10. C. Dane, H. Buyukasik, B. Dane and M. Yayla, Maternal plasma fibronectin and advanced oxidative protein products for the prediction of preeclampsia in high risk pregnancies: a prospective cohort study, Fetal Diagn Ther 26(4) (2009), 189-194.
11. T. Gredmark, B. Bergman and L. Hellstrom, Total fibronectin in maternal plasma as a predictor for preeclampsia, Gynecol Obstet Investig 47(2) (1999), 89-94. (Pubitemid 29082159)
12. R. Madazli, S. Aydin, S. Uludag et al., Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels, Acta Obstet Gynecol Scand 82(9) (2003), 797-802. (Pubitemid 37082907)
13. M. Swellam, N. Samy, S.A. Wahab and M.S. Ibrahim, Emerging role of endothelial and inflammatory markers in preeclampsia, Dis Markers 26(3) (2009), 127-133.
14. P. Galajda, P. Kubisz and M. Mokáň, A multicompartmental and multifactorial model of production of plasminogen activator inhibitor (PAI-1). I. Experimental studies, Vnitr Lek 44(12) (1998), 718-721.
15. I. Juhan-Vague, M.C. Alessi, A. Mavri et al., Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk, J Thromb Haemost 1(7) (2003), 1575-1579.
16. C. Catarino, I. Rebelo, L.Belo et al., Relationship betweenmaternal and cord blood hemostatic disturbances in preeclamptic pregnancies, Thromb Rev 123(2) (2008), 219-224.
17. Y.C. Teng, Q.D. Lin, J.H. Lin et al., Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts, J Perinat Med 37(4) (2009), 343-348.
18. B.J. Hunt, H.Missfelder-Lobos,M. Parra-Cordero et al., Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks, Thromb Haemost 7(6) (2009), 955-961.
19. S. Djurovic, T. Clausen, R. Wergeland et al., Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia, BJOG 109(7) (2002), 759-764. (Pubitemid 37329250)
20. M. Parra, R. Rodrigo, P. Barja et al., Screening test for preeclampsia through assessment of uteroplacental blood flow anf biochemical markers of oxidative stress and endothelial dysfunction, Am J Obstet Gynecol 193(4) (2005), 1486-1491. (Pubitemid 41395121)
21. G. Urban, P. Vergani, A. Ghidini et al., State of the Art: Ultrasound assessment for the uteroplacental circulation, Semin Perinatol 31(4) (2007), 232-239. (Pubitemid 47348103)
22. A.T. Papageorghiou, C.K.H. Yu, R. Bindra et al., Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation, Ultrasound Obstet Gynecol 18(5) (2001), 441-449. (Pubitemid 33078411)